NCT05222204View on ClinicalTrials.gov

DDP ip Combined With AG in PDAC With Peritoneal Metastasis

PHASE2CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

May 15, 2022

Primary Completion Date

July 8, 2024

Study Completion Date

December 12, 2024

Conditions
Pancreatic Neoplasm
Interventions
DRUG

intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel

intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel in patients with pancreatic cancer with peritoneal metastasis

Trial Locations (2)

200032

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER